Observational studyJournal of gastrointestinal cancer2026
Neoadjuvant Treatment Strategies in Unresectable Gallbladder Cancer (GBC) in a Regional Cancer Centre in India: a Prospective Cohort Study.
Observational study in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince GBC usually presents as unresectable disease, we conducted a prospective observational study to evaluate the effect of neoadjuvant strategies (NAT) on radiologic downstaging and resectability. MATERIALS AND
methodsPatients with locally advanced GBC were treated with neoadjuvant chemotherapy (NACT). Those who were unresectable after 4–6 cycles NACT were offered consolidation chemoradiotherapy [CTRT] (45 Gy along with weekly concurrent cisplatin, 5FU [prior to 2014] and thereafter concurrent capecitabine@1250mg/2). Radiological assessment of response to chemotherapy was done (by CT angiography and PET-CT) to evaluate for resectability. Features affecting resectability were evaluated. Those found suitable for resection underwent radical surgery.
results217 patients were evaluated (January 2012 to December 2022) (NACT:60%, NACT followed by CTRT:40%,). Pretreatment CT scans revealed involvement of liver>2 cm (75%), duodenum (42%), colon (29%), CBD (36%), CHD/primary confluence (45.6%), Hepatic Artery (32%), portal vein (21%), N0 (24.5%) N1 (17%), N2 (17%), retroperitoneal LN ( 40%). After NACT considerable radiological downstaging was evident in liver, duodenum and colon involvement (52%, 40% and 37%), while downstaging in CBD, CHD/confluence was relatively rare (14%, 7%). The proportion of nodal downstaging was evident from increase in proportion of N0 and N1 (37.5%, 20%), and decrease in proportion of N2 and RPLN (8%, 20%). Only 22 patients (10%) underwent surgical resection (EC n = 21, SC n = 1, after NACT:12, after CTRT:10). All except two were R0 (91%) and 48% had ypN0 disease. The median OS of those who underwent resection is 49 months (95% CI 26.8–69 mo.) versus 9 months (95% CI 8–10 mo.) in those who did not.
conclusionsNAT in unresectable GBC results in 10% resectability rate. Patients with liver involvement, duodenal involvement and lymphadenopathy had greater possibility of resectability after NAT, whereas those with biliary tree or vessel involvement had least possibility of resection. This approach has a potential of achieving R0, node negative disease leading to improved survival rates and should be actively explored in patients without biliary and vessel involvement.
Indexed as
Identifiers
41973362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.